Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides. (August 2021)

• Record Type: Journal Article
• Authors: Pfeil, Jennifer; Simonetti, Mario; Lauer, Uta; von Thülen, Bianca; Durek, Pawel; Poulsen, Christina; Pawlowska, Justyna; Kröger, Matthias; Krähmer, Ralf; Leenders, Frank; Hoffmann, Ute; Hamann, Alf
• Is Part Of: Therapeutic advances in chronic disease. Volume 12(2021)
• Publication Date: 2021-08
• Subjects: allergy -- autoimmunity -- chronic autoimmune disease -- drug delivery -- experimental autoimmune encephalomyelitis -- multiple sclerosis -- peptide vaccination -- regulatory T cells -- specific immunotherapy (SIT) -- therapy -- tolerance induction; Chronic diseases -- Periodicals; Chronic diseases -- Treatment -- Periodicals; Chronic Disease -- Periodicals; Chronic Disease -- therapy -- Periodicals; 616.044
• DOI: 10.1177/20406223211037830
• Languages: English
• ISSNs: 2040-6223

Abstract

Background: Therapeutic treatment options for chronic autoimmune disorders such as multiple sclerosis (MS) rely largely on the use of non-specific immunosuppressive drugs, which are not able to cure the disease. Presently, approaches to induce antigen-specific tolerance as a therapeutic approach; for example, by peptide-based tolerogenic 'inverse' vaccines have regained great interest. We have previously shown that coupling of peptides to carriers can enhance their capacity to induce regulatory T cells in vivo . Method: In this present study, we investigated whether the tolerogenic potential of immunodominant myelin T-cell epitopes can be improved by conjugation to the synthetic carrier polyethylene glycol (PEG) in an experimental autoimmune encephalomyelitis (EAE) mouse model for chronic MS (MOG C57BL/6). Results: Preventive administration of the PEGylated antigenic peptide could strongly suppress the development of EAE, accompanied by reduced immune cell infiltration in the central nervous system (CNS). Depletion of regulatory T cells (Tregs) abrogated the protective effect indicating that Tregs play a crucial role in induction of antigen-specific tolerance in EAE. Treatment during the acute phase of disease was safe and did not induce immune activation. However, treatment at the peak of disease did not affect the disease course, suggesting that either induction of Tregs does not occur in the highly inflamed situation, or that the immune system is refractory to regulation in this condition. Conclusion: PEGylation of antigenic peptides is an effective and feasible strategy to improve tolerogenic (Treg-inducing) peptide-based vaccines, but application for immunotherapy of overt disease might require modifications or combination therapies that simultaneously suppress effector mechanisms.